Business Wire

MA-IHRDC

29.7.2024 06:16:37 CEST | Business Wire | Press release

Share
Stepping Into the Future: IHRDC’s New Home in Historic Boston Bridges Tradition with Innovation

IHRDC, a worldwide leader in energy industry training, is excited to announce the relocation of its main office to a new location in the company’s long-time home base in the Back Bay neighborhood of Boston, Massachusetts. The move from Boylston Street to Park Plaza, just half a mile away, reflects the company’s dedication to better serving IHRDC’s learning and development clients and support its growing team.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240728136557/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

New Headquarters for IHRDC: The global energy industry training leader is moving to the historic Saunders Building in Boston's Back Bay neighborhood. (Photo: Business Wire)

New address effective August 1, 2024:

20 Park Plaza, Suite 900, Boston, MA 02116 USA

Located in the historic Saunders Building, the new office provides a refreshed, modern office environment and historic charm. Highlights include an on-site training center, accommodations at the adjacent Hilton Park Plaza Hotel, and close proximity to the beautiful Boston Public Garden.

“This move is a strategic step to expand our operations and enhance our facilities to support our ongoing mission of developing people,” said IHRDC President & CEO Brad Donohue. “The new headquarters offers the flexible space and improved office layout we need to better accommodate our staff and meet the evolving needs of our business partners.”

IHRDC is committed to ensuring a smooth transition with minimal disruption to its services. Operations will continue as usual, with no anticipated downtime during the move.

Important Information:

  • New Address: 20 Park Plaza, Suite 900, Boston, MA 02116 USA
  • Phone Number: +1-617-536-0202 (remains unchanged)
  • Email: corporate@ihrdc.com (remains unchanged)

Clients, service-providers and friends are kindly requested to update their records using the new address. For your convenience, here is a map of the new location, including parking and public transportation options: https://www.google.com/maps/place/20+Park+Plaza,+Boston,+MA+02116/

“Thank you to our customers, partners, friends and families for their continued support and understanding as we make this exciting transition,” commented CEO Donohue. “We look forward to welcoming you all – future participants, alumni and existing clients – to our new headquarters and continuing to develop competence for the energy industry.”

About IHRDC:
International Human Resources Development Corporation (www.ihrdc.com) has been a global leader in training and competency development for the oil and gas industry for 55 years, offering the best Instructional Programs, e-Learning and Knowledge Solutions, and Competency Management products and services available to the industry today. The company is headquartered in Boston, USA with offices in London, Amsterdam, Abu Dhabi, Kuala Lumpur, and Lagos.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240728136557/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release

- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C

Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release

The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag

Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda

Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release

Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm

No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 14:48:00 CEST | Press release

Rapid growth shows strong demand for a new trading model where users can make market predictions without risking their own capital Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye